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Abstract
The pervasive view of bacteria as strictly pathogenic has given way to an appreciation of the 
widespread prevalence of beneficial microbes within the human body1–3. Given this milieu, it is 
perhaps inevitable that some bacteria would evolve to preferentially grow in environments that 
harbor disease and thus provide a natural platform for the development of engineered therapies4–6. 
Such therapies could benefit from bacteria that are programmed to limit bacterial growth while 
continually producing and releasing cytotoxic agents in situ7–10. Here, we engineer a clinically 
relevant bacterium to lyse synchronously at a threshold population density and to release 
genetically encoded cargo. Following quorum lysis, a small number of surviving bacteria reseed 
the growing population, thus leading to pulsatile delivery cycles. We use microfluidic devices to 
characterize the engineered lysis strain and we demonstrate its potential as a drug delivery 
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platform via co-culture with human cancer cells in vitro. As a proof of principle, we track the 
bacterial population dynamics in ectopic syngeneic colorectal tumors in mice. The lysis strain 
exhibits pulsatile population dynamics in vivo, with mean bacterial luminescence that remained 
two orders of magnitude lower than an unmodified strain. Finally, guided by previous findings that 
certain bacteria can enhance the efficacy of standard therapies11, we orally administer the lysis 
strain, alone or in combination with a clinical chemotherapeutic, to a syngeneic transplantation 
model of hepatic colorectal metastases. We find that the combination of both circuit-engineered 
bacteria and chemotherapy leads to a notable reduction of tumor activity along with a marked 
survival benefit over either therapy alone. Our approach establishes a methodology for leveraging 
the tools of synthetic biology to exploit the natural propensity for certain bacteria to colonize 
disease sites.
In order to control population levels and facilitate drug delivery using bacteria, we 
engineered a synchronized lysis circuit (SLC) using coupled positive and negative feedback 
loops that have previously been used to generate robust oscillatory dynamics12,13. The 
circuit (Fig. 1a) consists of a common promoter that drives expression of both its own 
activator (positive feedback) and a lysis gene (negative feedback). Specifically, the luxI 
promoter regulates production of autoinducer (AHL), which binds LuxR and enables it to 
transcriptionally activate the promoter. Negative feedback arises from cell death that is 
triggered by a bacteriophage lysis gene (ϕX174 E) which is also under control of the luxI 
promoter13–15. Importantly, AHL can diffuse to neighboring cells and thus provides an 
intercellular synchronization mechanism.
The bacterial population dynamics arising from the synchronized lysis circuit can be 
conceptualized as a slow buildup of the signaling molecule (AHL) to a threshold level, 
followed by a lysis event that rapidly prunes the population and enables the release of 
bacterial contents (Fig. 1b). After lysis, a small number of remaining bacteria begin to 
produce AHL anew, allowing the “integrate and fire” process to be repeated in a cyclical 
fashion. We used microfluidic devices to observe growth and lysis with a fluorescent protein 
(sfGFP) as a proxy for circuit dynamics in attenuated S. typhimurium (Supplementary 
Videos 1 and 2). We observed periodic lysis events characterized by peaks in the fluorescent 
reporter expression that correspond to population lysis (Fig. 1c). The fraction of lysed cells 
remains consistent across subsequent cycles, suggesting that lysis and survival occur in a 
stochastic manner (Extended Data Fig. 1a-b). Given the ultimate goal of implementation in 
an in vivo microenvironment characterized by variable growth conditions, we tested a range 
of incubation temperatures (36°C to 40°C) and perfusion rates (100μm/s to 200μm/s), 
measuring an average period of 3 hours across all conditions (Fig. 1d). These findings 
demonstrate that the SLC has the capacity to generate robust cycles of bacterial lysis in our 
microfluidic devices across a spectrum of environmental fluctuations that is likely to exist in 
an in vivo context.
The emergence of bacterial therapies in synthetic biology has accentuated the need for 
predictive modeling. This need stems from a bottleneck created by a difference in the 
timescales for bacterial cloning versus animal experiments; the circuits required for 
candidate therapies can be created much faster than they can be tested in vivo. Therefore, in 
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order to quantitatively characterize the SLC concept before testing in animal models, we 
developed a computational model (Fig. 2a and and Supplementary Information) in order to 
define an optimal strategy for subsequent testing in a lower-throughput animal model 
setting. We found that high production and degradation rates of the feedback-controlling 
proteins resulted in a wider domain of oscillatory dynamics in the parameter space (Fig. 2b). 
This model is consistent with our observations that oscillations in S. typhimurium were more 
robust than in E. coli, where rates of protein production and degradation were previously 
found to be lower16 (Extended Data Fig. 1c and Supplementary Video 3). Since the ability to 
manipulate circuit behavior enhances the versatility of the system, we explored the tunability 
of the lysis period by adding an ssrA degradation tagging sequence on the LuxI protein. 
Consistent with model predictions, we observed an increased period and colony firing 
amplitude when tracking bacterial population dynamics (Fig. 2c-d and Extended Data Fig. 
1d). The SLC thus enables tuning of the period and magnitude of delivery, which will be 
necessary for eventual application of this platform in the complex and fluctuating conditions 
present in vivo.
To incorporate a cytotoxic payload into the SLC strain, we added expression of Hemolysin 
E, encoded by hlyE of E. coli, which has been tested as a pore-forming anti-tumor toxin17. 
We initially confirmed the capability of the circuit to release intracellular contents by 
visualizing released sfGFP with a small microfluidic sink located beneath the growth 
chamber (Extended Data Fig. 2a-c). Then, in order to visualize bacterial lysis and killing of 
cancer cells in vitro via HlyE, we engineered a microfluidic device so that cancer cells 
adhere inside a growth channel that is flanked by smaller bacterial growth chambers, which 
permits simultaneous single-cell visualization of bacterial lysis and cancer cell death 
(Extended Data Fig. 2d). After co-culturing human cervical cancer HeLa cells with S. 
typhimurium harboring the SLC circuit, we observed HeLa cell death upon the onset of 
bacterial lysis, indicating efficient toxin release (Fig. 3a-b, Supplementary Videos 4 and 5). 
Complete cell death occurred in the growth channel within ~111 min of initial sfGFP 
fluorescence (Fig. 3c). Thus, the SLC bacteria were capable of releasing HlyE at levels 
necessary to kill tumor-derived cells.
We assessed the toxicity of released SLC or control bacterial contents in batch culture. As 
anticipated, we found that HeLa cells exposed to supernatant from a culture of the SLC 
bacteria bearing the hlyE module exhibited almost complete loss of viability (Fig. 3d), while 
the viability of HeLa cells exposed to supernatants of and equivalent dose of non-payload 
bearing SLC bacteria were only slightly impacted (~15%). We concluded that bacterial lysis 
allowed for efficient HlyE release in vitro and that natural intracellular bacterial contents do 
not significantly affect HeLa cell viability. We further investigated the delivery 
characteristics of the SLC bacteria with hlyE by seeding variable amounts of circuit-
harboring bacteria with HeLa cultures in well plates. We observed that the time to HeLa cell 
death following initial seeding increased with lower bacterial seeding volumes, presumably 
resulting from the extended time needed for bacteria to reach the quorum threshold (Fig. 3e 
and Supplementary Video 6). Initial seeding with a larger volume of bacteria resulted in 
increased firing rates which corresponded to shorter HlyE exposure times until cell death, 
consistent with a greater magnitude of lysis and payload release, although the cumulative 
toxicity threshold appears to be similar in all cases (Fig. 3f). Based on these observations, 
Din et al. Page 3
Nature. Author manuscript; available in PMC 2017 February 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
one can adjust the seeding size of the bacterial population to determine the initial timing and 
release characteristics of the circuit.
We next used a luciferase reporter to monitor bacterial population dynamics in grafted 
syngeneic colorectal tumors in mice. To minimize the extent of plasmid loss in the absence 
of antibiotic selection in vivo, we incorporated previously described stabilizing elements for 
plasmid retention and segregation into the SLC strain18–22. Additionally, we placed both the 
payload and luxCDABE genes (the in vivo reporter module) under the luxI promoter as an 
indicator of hlyE production and quorum firing via bacterial luminescence (Fig. 1a). Using a 
subcutaneous model of colorectal cancer (MC26 cell line) in immunocompetent mice, we 
intratumorally injected a strain of SLC bacteria (SLC-hly). We observed pulsatile bacterial 
population dynamics within the tumor (Fig. 4a-c, Extended Data Fig. 3a-b) using In-Vivo 
Imaging (IVIS) technology23, consistent with the design and in vitro characterization (Fig. 
2). Importantly, the end luminescence intensity was on average ~300-fold lower than the 
constitutive control strain, indicating a significant decrease in bacterial population levels 
within the tumor (Extended Data Fig. 3c).
Given the ability to engineer bacterial population dynamics in tumor grafts, we next 
leveraged the versatility of the SLC bacteria as a delivery system to compare different 
classes of previously developed payloads. In addition to the hemolysin strain that was 
characterized in microfluidic devices, we created two additional SLC strains expressing 
genes to activate a host immune response (via T-cell and dendritic cell recruitment, using 
mCCL21) or trigger tumor cell apoptosis (using CDD-iRGD)24,25. Upon intratumoral 
injection, the immune recruitment strain elicited the strongest effect on tumor growth when 
compared to the hemolysis or apoptotic strains (Fig. 4d). We observed that an equal mixture 
of the three strains generated a stronger response than any single strain (Fig. 4d and 
Extended Data Fig.3 e-g), and on this basis we elected to pursue the “triple-strain” dose for 
further testing in order to minimize animal usage. In a side by side comparison, we observed 
that the tumor response to SLC triple-strain (SLC-3) injections was significantly larger than 
the response to unmodified bacteria (Fig. 4e). Additionally, upon necropsy, histopathological 
analysis of remnant tumors was performed for mice treated with the SLC-3 strains, 
chemotherapy, or unmodified bacteria. In mice treated with SLC-3 and non-circuit bacterial 
strains, robust staining of bacteria was observed by anti-Salmonella antibodies, showing 
localization of Salmonella within tumors. TUNEL staining indicated higher levels of 
apoptosis and cell death in SLC-3 treated tumors (Extended Data Fig. 4).
As a first step towards monitoring the effect of bacterial injections on the host, we compared 
how the triple-strain system affected body weight when administered intratumorally and 
intravenously, since the administration route affects bacterial localization (Extended Data 
Fig. 3d). We found that treatment with the SLC strains generated the same weight change as 
unmodified bacteria when administered intratumorally (Fig. 4f). However, intravenous 
administration of the SLC conferred a greater health benefit based on observations that SLC 
strains producing constitutive therapy were better tolerated than unmodified bacteria or non-
SLC strains producing constitutive therapy (Fig. 4g). While further targeted studies are 
required to systematically explore the impact of these bacteria on host health, these 
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preliminary experiments suggest that the SLC design can reduce the burden of bacterial 
injections.
To explore a proof-of-principle for the application of our circuit in the context of in vivo 
tumors, we examined the efficacy of our system in an experimental syngeneic 
transplantation model of colorectal metastases within the liver. We had previously 
established that oral delivery of these bacterial strains led to safe and efficient colonization 
of hepatic colorectal metastases (see Methods), and that mice tolerated repeated dosing 
without overt adverse effects (Fig. 5a-b)22. In the context of bacteria-based therapeutic 
candidates, previous studies have shown that anaerobic bacteria can occupy avascular tumor 
compartments where chemotherapy is thought to be ineffective due to poor drug delivery11. 
Thus a synergistic effect may arise when bacteria are used to deliver drugs to the necrotic 
core of a tumor, while standard chemotherapy is used for the vascularized regions11,26. 
Inspired by this paradigm, we tested the combination of SLC-3 bacteria with a common 
clinical chemotherapy (5-fluorouracil, 5-FU). Tumors exhibited similar growth trajectories 
in response to repeated oral delivery of either the bacterial therapy alone, or two i.v. doses of 
5-FU on Days 0 and 21 (Fig. 5c). In contrast, combination of these two applications led to a 
marked decrease in tumor activity over a period of 18 days, followed by a return to growth 
(Fig. 5d). During the initial 18-day period, a large fraction of the tumors were scored as 
eliciting at least a 30% reduction in tumor activity (Fig. 5e). The overall response led to 
roughly a 50% increase in the mean survival time for animals harboring incurable colorectal 
metastases (Fig. 5f). Improvements may arise from strategies for long term circuit stability 
or the utilization of additional therapeutic cargo.
The synchronized lysis circuit exemplifies a methodology for leveraging the tools of 
synthetic biology to exploit the ability of certain bacteria to colonize disease sites. In 
contrast to most drug delivery strategies, the synchronized lysis paradigm does not require 
pre-loading of a drug or the engineering of additional secretion machinery. In addition, it has 
the potential to decrease the likelihood of a systemic inflammatory response through 
population control; since the bacterial colony is pruned after each oscillatory lysis event, the 
design could mitigate an undesirable host response. The circuit may enable new bacterial 
drug delivery strategies through modulation of the frequency and amplitude of the 
population cycles over time. Along these lines, cyclic drug release may have broader 
implications, given recent insights into the effects of circadian rhythms on host-microbial 
interactions and metabolic disorders27,28. Such engineering strategies may allow for the 
development of therapeutic communities within in vivo environments, where population 
dynamics are driven by interacting viruses, bacteria, and host immune cells29.
Methods
Strains and Plasmids
Our circuit strains were cultured in LB media with 50 μg ml−1 and 34 μg ml−1 of Kanamycin 
and Chloramphenicol respectively, along with 0.2% glucose, in a 37°C incubator. 
Mammalian cells (HeLa CCL-2 from ATCC, verified by third party cell line authentication 
services using an STR multiplex system) were cultured in DMEM media supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin (CellGro 30-002-CI), placed inside 
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a tissue culture incubator at 37°C maintained at 5% CO2. Plasmids were constructed using 
the CPEC method of cloning or using standard restriction digest/ligation cloning. The 
activator plasmid (Kan, ColE1) was used in previous work from our group, while the lysis 
plasmid was constructed by taking the lysis gene, E, from the ePop plasmid via PCR and 
cloning it into a vector (Chlor, p15A) under the control of the LuxI promoter13,15. The hlyE 
gene was taken via PCR from the genomic DNA of MG1655, while mCCL21 (mouse 
CCL21) and CDD-iRGD were synthesized. These genes were cloned into the lysis plasmid, 
under the control of either the ptac or pLuxI promoters. Co-culturing was performed with 
HeLa cells and either motile or non-motile S. typhimurium, SL1344. For full strain and 
plasmid information, please refer to the Supplementary Information.
Microfluidics and Microscopy
The microfluidic devices and experiment preparation protocols used in this study are similar 
to those previously reported from our group13. The bacteria growth chambers were 100×100 
μm in area and approximately 1.4 μm in height. For co-culture experiments on the chip, we 
first loaded a suspended culture of HeLa cells in the device media channels at very low flow 
rates, to allow for adherence, and then incubated the device in a tissue culture incubator for 
0.5 - 2 days to allow for proliferation. On the day of the experiment, the device was 
transferred to the microscope and circuit-containing bacteria were loaded in the growth 
chambers before imaging. Acquisition of images was performed with a Nikon TI2 using a 
Photometrics CoolSnap cooled CCD camera. The scope and accessories were programmed 
using the Nikon Elements software. Additional details on microfluidics and microscopy can 
be found in the Supplementary Information.
In vivo Experiments
All animal work was approved by the committee on animal care (MIT, protocol 
0414-022-17). The cell line (MC26-LucF, Tanabe lab, Massachusetts General Hospital) was 
obtained from, and authenticated by, the Tanabe lab, MGH. The cell line was tested several 
times to be mycoplasma free before implantation in mice. Sample sizes for mice were 
determined by expected effect size to produce a power of 0.8-0.9. Mice were blindly 
randomized into various groups using a random number generator.
Subcutaneous Tumor Model—Animal experiments were performed on 6 week old 
female BALB/c mice (Taconic Biosciences, Inc.) with bilateral subcutaneous hind flank 
tumors from an implanted mouse colon cancer cell line. The concentration for implantation 
of the tumor cells was 1e8 cells ml−1 in DMEM (no phenol red). Cells were then implanted 
subcutaneously at a volume of 100 μL per flank, with each implant consisting of 1e7 cells. 
Tumors were typically grown to an average of 300 mm3 before experiments.
Experimental Liver Metastasis Model—The experimental metastasis model was 
generated by injecting luciferase-producing mouse cancer cells into surgically externalized 
spleens of immuno-competent mice. Tumor cells seeded the liver during 90 seconds after 
which the spleen was removed to prevent ectopic tumor growth30. The MC26-LucF cell line 
was used (Tanabe Lab, MGH) and injected at 5e4 cells/100 uL PBS into the spleens of 
female Balb/c mice 6 weeks of age (Taconic Biosciences, Inc.). For the liver metastasis 
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model, tumors were grown for 5-7 days to an average total tumor burden of 143 mm3 before 
experiments.
Bacterial Growth and Administration—Bacterial strains were grown overnight in LB 
media containing appropriate antibiotics and 0.2% glucose as for the in vitro experiments. A 
1/100x dilution in fresh media with antibiotics was started the day of injection and grown 
until an OD < 0.1 to prevent bacteria from reaching the quorum threshold (for SLC 
specifically). Bacteria were spun down and washed 2-3x with sterile PBS before injection 
into mice. Intratumoral injections of bacteria were performed at a concentration of 5e7 cells 
ml−1 in PBS with a total volume of 10-20 μL injected per tumor, while intravenous 
injections were given at a total volume of 100 μL. For the SLC-3 strains injection, this final 
volume was equally divided between the three strains at the indicated density. For liver 
metastasis experiments, bacteria were grown in LB media containing appropriate antibiotics 
and 0.2% glucose until they reached an OD of 0.05, after which they were concentrated to 
1-5e9 bacteria/mL and delivered via oral gavage.
Post-Administration Monitoring for Subcutaneous Liver Metastasis Models—
Luminescent signal was measured with the IVIS Spectrum in vivo imaging system following 
bacterial injection. Measurements were compared relative to pre-injection values to follow 
dynamics. Subcutaneous tumor volume was quantified using calipers to measure the length, 
width, and height of each tumor throughout the imaging course (V=L×W×H). Volumes were 
compared to pre-injection values to follow physical tumor growth. Survival of mice was 
measured as the time from the beginning of the experiment up to the day when mice were 
moribund and euthenized.
Statistical Analysis
Statistical tests were calculated either in Microsoft Excel (Student's t-test) or GraphPad 
Prism 5.0 (ANOVA with Bonferroni post test, Log-rank test). The details of the statistical 
tests carried out are indicated in respective figure legends. Where data were approximately 
normally distributed, values were compared using either a Student's t-test or one-way 
ANOVA for single variable, or a two-way ANOVA for two variables. Mice were randomized 
in different groups before experiments.
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Extended Data
Extended Data Fig. 1. 
Various properties of the SLC. (a) The fraction and number of bacterial cells cleared per 
consecutive oscillatory cycle in the growth chamber for a typical microfluidic experiment for 
S. typhimurium, including the effects of lysis and flow of cells outside of the trap (Strain 1). 
(b) Subset of time series images from the experiment in (a) showing a portion of the growth 
chamber where survivors of the initial lysis event (160 min frame, red outline) produce 
progeny (250 min frame, magenta outline) which are lysis sensitive. (c) Period as a function 
of the environmental temperature for E. coli (Strain 13). The circuit does not oscillate for 
temperatures above 37°C in E. coli. Error bars indicate ±1 standard deviation for 12 - 19 
peaks. (d) Colony amplitude at quorum firing for increasing degradation on the LuxI 
activator protein in the computational model. These simulation results are supported by 
batch well-plate experiments of the LuxI ssrA (black line, Strain 2) and non-ssrA (blue line, 
Strain 1) tagged versions of the circuit in S. typhimurium (inset).
Extended Data Fig. 2. 
Investigating lysis mediated intracellular release. (a) A bacterial growth chamber with a 
0.4μm sink for sfGFP visualization after release. (b) Number of bacteria (red line), bacterial 
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fluorescence (blue line), sink fluorescence (pink line) for a typical oscillatory cycle (Strain 
1). (c) Fluorescence time series images of the microfluidic sink from (b). (d) General 
procedure for performing bacterial and cancer cell co-culture experiments in a microfluidic 
device (also see Supplementary Information).
Extended Data Fig. 3. 
In vivo expression and therapy testing. (a) End-point in vitro luminescence intensity for SLC 
strains after ~20 h of growth. Host strains A and B are the host bacteria for Strains 8 and 10. 
They are ELH1301 and ELH 430, respectively. Host A exhibits ~2-fold higher luminescence 
with the same circuit than Host B. (b) IVIS imaging over time of a mouse bearing 
subcutaneous tumors injected with a genomically integrated constitutively luminescent strain 
(Strain 9). (c) End-point in vivo bacterial luminescence of the SLC-hly strain and the 
constitutively luminescent strain from the experiments presented in Fig. 4. Error bars 
represent the standard error of the mean bacterial luminescence from 9 tumors. (d) Post-
injection in vivo bacterial luminescence for the constitutively luminescent strain 
administered intravenously (vein) or intratumorally (tumor). Luminescence was measured 
~20 h post-injection. Error bars represent the standard error of the mean bacterial 
luminescence from 6 and 9 tumors for the intravenous and intratumoral cases, respectively. 
(e) Average relative tumor volume over time for subcutaneous tumor bearing mice injected 
with the no-plasmid bacterium (Strain 7), 5-FU chemotherapy, the SLC-3 strains, and the 
combination of SLC-3 with chemotherapy. Bacteria were injected intratu-morally on days 0, 
4, and 7 (black arrows), and chemotherapy was administered on days 2 and 9 (red arrows) 
(*P < 0.05, ****P < 0.0001, two-way ANOVA with Bonferroni post test, n = 12 - 16 tumors, 
s.e.). (f) Fraction of mice from the cases in (e) which respond with 30% reduction of tumor 
volume over time. (g) Fraction survival over time for mice with hepatic colorectal metastases 
fed with either the SLC-3 strains (blue line) or the no-plasmid control (black line) (*P < 
0.05, log rank test; n = 11 - 12 mice).
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Extended Data Fig. 4. 
(a) Histology of tumor sections taken from mice with different treatments 3 days post 
administration: (i) H and E staining for tissue sections intravenously injected with a 
combination of therapeutic bacteria (SLC-3), chemotherapy (5-FU), or a bacteria control 
with no therapeutic (Strain 7). (ii) TUNEL staining (red) in the same sections indicating cell 
apoptosis. (iii) Salmonella immunohistochemistry (red) in the same sections confirming 
presence of bacteria in tumors. Scale bars for (i), (ii), and (iii) denote 50μm. (iv) and (v) 
TUNEL and Salmonella staining (red) in the entire tumor sections (examples indicated by 
arrows). Scale bars for (iv) and (v) denote 100μm. DAPI staining (blue) was used to obtain a 
measure of live and dead cells in (ii) - (iv). Histology slices (n=6) from 20x images were 
compared across the groups and mean intensity of TUNEL staining, normalized by sample 
area, was demonstrated to be significantly higher for SLC-3 compared to the other two 
groups (P<0.0001, one-way ANOVA), and not significantly different between the 
chemotherapy and bacteria only cases.
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Extended Data Fig. 5. 
Shown are the main plasmids used in this study (see Supplementary Information for more 
details).
Extended Data Table 1
A list of strains and respective plasmids used in this study (see Supplementary Information 
for more details).
Strain # Strain Name Host Bacterium Plasmid(s)
1 MOD47 SL1344, M913 pTD103 luxI (−LAA) sfGFP + pZA35 X714E (+LuxR)
2 MOD46a SL1344, M913 pTD103 luxI sfGFP + pZA35 X714E (+LuxR)
3 MOD67 SL1344, M913 pTD103 luxI (−LAA) sfGFP + pZA35 X714E (+LuxR) 
ptac::HlyE
4 MOD61 SL1344, ELH1301 pTD103 luxI sfGFP + pZA35 X714E (+LuxR) ptac::HlyE
5 MOD64 SL1344, ELH1301 pTD103 luxI sfGFP + pZA35 X714E (+LuxR)
6 MOD65 SL1344, ELH1301 pZA35 ptac::HlyE
7 ELH1301 SL1344, ELH1301 N/A
8 MOD105 SL1344, ELH430 pZE25 luxI luxCDABE hok/alp + pZA35 X714E (+LuxR) 
pLux::HlyE hok/alp
9 EcN-luxCDABE Nissle 1917 N/A
10 MOD101 SL1344, ELH1301 pZE25 luxI luxCDABE hok/alp + pZA35 X714E (+LuxR) 
pLux::HlyE hok/alp
11 MOD102 SL1344, ELH1301 pZE25 luxI luxCDABE hok/alp + pZA35 X714E (+LuxR) 
ptac::HlyE hok/alp
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Strain # Strain Name Host Bacterium Plasmid(s)
12 MOD69 SL1344, ELH1301 pTD103 LuxCDABE hok/alp + pZA35 X714E (+LuxR) 
ptac::HlyE hok/alp
13 MOD29 JS006, BW25113 pTD103 luxI sfGFP + pZA35 X714E (+LuxR)
14 MOD110 SL1344, ELH1301 pZE25 luxI luxCDABE hok/alp + pZA35 X714E (+LuxR) 
pLux::CDD-iRGD hok/alp
15 MOD112 SL1344, ELH1301 pZE25 luxI luxCDABE hok/alp + pZA35 X714E (+LuxR) 
ptac::mCCL21 hok/alp
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Construction and characterization of the SLC. (a) The circuit contains an activator13 and 
lysis plasmid. When the population reaches the quorum threshold at a critical AHL 
concentration, the luxI promoter drives the transcription of gene E for lysis, LuxI, and sfGFP 
or luxCDABE as the reporter module. The luxI or the ptac promoter also drives the 
transcription of the therapeutic gene for the stabilized circuit used in vivo. LuxR in this 
system is driven by the native pLuxR promoter. (b) A schematic that illustrates the main 
stages of each lysis cycle from seeding to quorum ‘firing’. Shown below are typical time 
series images of the circuit-harboring cells undergoing the three main stages of quorum 
firing in a microfluidic growth chamber12. (c) Fluorescence profile of a typical microfludic 
experiment. The estimated cell population trajectory reveals that lysis events correspond to 
peaks of sfGFP fluorescence. (d) Period as a function of estimated flow velocity in the 
media channel of the microfluidic device and environmental temperature. Error bars indicate 
±1 standard deviation for 13 - 50 peaks. The above experiments were performed with Strain 
1, see Supplementary Information for complete strain information.
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Fig. 2. 
Computational modeling and tunability. (a) The model consists of intracellular variables 
(lysis gene E and LuxI concentrations) and extracellular variables (colony size and AHL 
concentrations). A time series of colony size (black line), colony AHL (blue line), 
intracellular LuxI (green line) and lysis protein concentrations (red line) are shown on the 
right. (b) The region in the model parameter space for clpXP mediated degradation (see 
Supplementary information) and flow where the model output is oscillatory increases with 
higher production and degradation terms. (c) Results from the computational model showing 
the ability to tune the oscillatory period by varying ClpXP mediated degradation of LuxI. (d) 
Fluorescence profiles showing lysis oscillations for LuxI ssrA (black line, Strain 2) and non-
ssrA (blue line, Strain 1) tagged versions of the circuit. See Supplementary Information for 
complete model information.
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Fig. 3. 
In vitro co-culture. (a) Schematic of the microfluidic co-culture with cancer cells and 
bacteria. Fluidic resistance was modified in this chip to achieve stable near-stagnant flow 
reduction to allow for cancer cell adherence and for diffusion of released therapeutic from 
the trap to the channel (methods in Supplementary Information). (b) Frames from the co-
culture time series sequentially visualizing S. typhimurium (Strain 3) ‘firing’, lysis, and 
HeLa cell death. (c) Fluorescent profile of the bacteria and HeLa cell viability fraction (# 
live cells / # dead cells in image frames) from (b) with time. (d) % viability of HeLa cells 
co-cultured with supernatant from S. typhimurium culture harboring the SLC + HlyE (Strain 
4), the SLC only (Strain 5), constitutive hlyE only (Strain 6), or no plasmid (Strain 7). Error 
bars indicate ±1 standard error averaged over three measurements. (e) Fluorescence profile 
of the SLC + HlyE (Strain 4) co-cultured with HeLa cells at various initial seeding densities. 
The black ‘x’ marks the point of complete HeLa cell death. (f) The toxin exposure time, 
measured from the initial presence of fluorescence to HeLa cell death, as a function of the 
sfGFP production rate (see example in (e)). Although the time to death depends on seeding, 
the total magnitude of exposure remains conserved (inset). Error bars indicate ±1 standard 
error for three measurements. See Supplementary Information for ELH1301 host strain 
information.
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Fig. 4. 
In vivo bacterial dynamics, tumor impact, and tolerability in a subcutaneous tumor model. 
(a) IVIS imaging over time of a mouse bearing two hind flank tumors injected once with the 
stabilized SLC-hly strain (Strain 8). (b) Single tumor density map trajectories of bacterial 
luminescence (relative to luminescence at 0h) for the SLC-hly strain (Strain 8). Data for 
each axis represents separate experiments. (c) Single tumor density map trajectories of 
bacterial luminescence for the genomically integrated constitutively luminescent strain 
(Strain 9). Intratumoral injection resulted in over 35-fold higher post-injection luminescence 
compared to intravenous injection (Extended Data Fig. 3d). (d) Average relative tumor 
volume over time for subcutaneous tumor bearing mice injected with SLC-hly (red line, 
Strain 10), SLC-cdd (green line, Strain 14), SLC-ccl21 (blue line, Strain 15), and all together 
(SLC-3) (black line). Bacteria were injected intratumorally on days 0, 2, 6, 8, and 10 (black 
arrows) (****P < 0.0001, two-way ANOVA with Bonferroni post test, n = 14 - 17 tumors, 
s.e.). (e) Average relative tumor volume over time for mice with subcutaneous tumors 
injected with the SLC-3 strains (black line, Strain 10, 14, and 15) and the no-plasmid control 
(magenta line, Strain 7). Bacteria were injected intratumorally on days 0, 2, 6, and 10 (black 
arrows) (****P < 0.0001, two-way ANOVA with Bonferroni post test, n = 18 - 19 tumors, 
s.e.). (f) Average relative body weight over time for mice with subcutaneous tumors injected 
with the SLC-3 strains (black line, Strain 10, 14, and 15) and the no-plasmid control 
(magenta line, Strain 7). Bacteria were injected intratumorally on days 0, 2, 6, and 10 (black 
arrows) (n=10 mice for both cases, s.e.). (g) Average relative body weight over time for 
subcutaneous tumor-bearing mice with a single intravenous injection of the SLC + 
constitutive hlyE (turquoise line, n=9 mice, Strain 11), a non-SLC strain with constitutive 
hlyE (orange line, n=5 mice, Strain 12), or the no-plasmid control strain (magenta line, n=9 
mice, Strain 7) (***P < 0.001, two-way ANOVA with Bonferroni post test, s.e.).
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Fig. 5. 
In vivo testing in an experimental model of colorectal metastases in the liver via oral 
delivery of bacteria. (a) Schematic of the experimental syngeneic transplantation model of 
hepatic colorectal metastases in a mouse, with the dosing schedule of either engineered 
bacteria (SLC-3) or a common cytotoxic chemotherapeutic, the antimetabolite 5-FU. The 
SLC-3 strains were delivered orally while 5-FU was delivered via intraperitoneal injection. 
(b) Relative body weight over time for the mice with with hepatic colorectal metastases fed 
with the SLC-3 strains (blue line), injected with 5-FU chemotherapy (red line), or a 
combination of the two (green line). Error bars indicate ±1 standard error for 5 - 7 mice. (c) 
Median relative tumor activity, measured via tumor cell luminescence using IVIS imaging, 
for the chemotherapy and SLC-3 cases from (b). (d) Median relative tumor activity for the 
combination therapy case from (b). Error bars for (c) and (d) indicate the interquartile ranges 
for 5 - 7 mice. The dashed line marks relative tumor activity of 0.70. (e) Fraction of mice 
from the cases in (b) which respond with 30% reduction of tumor activity over time. (f) 
Fraction survival over time for the mice in (b) (**P < 0.01, log rank test; n = 5 - 7 mice).
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